LivaNova (NASDAQ:LIVN) Price Target Cut to $60.00 by Analysts at Mizuho

LivaNova (NASDAQ:LIVN) had its target price lowered by Mizuho from $70.00 to $60.00 in a research report released on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research firms also recently commented on LIVN. Robert W. Baird increased their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday. Needham & Company LLC reduced their price target on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $64.20.

LivaNova Trading Down 0.6 %

NASDAQ LIVN opened at $41.45 on Wednesday. LivaNova has a 12 month low of $40.37 and a 12 month high of $64.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 98.69 and a beta of 1.00. The company’s fifty day moving average price is $47.65 and its two-hundred day moving average price is $49.56.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC increased its holdings in shares of LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after acquiring an additional 1,441 shares during the period. Central Pacific Bank Trust Division increased its holdings in shares of LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares during the period. Captrust Financial Advisors acquired a new stake in shares of LivaNova in the 3rd quarter worth about $217,000. Finally, Sanctuary Advisors LLC acquired a new position in LivaNova during the 3rd quarter valued at about $219,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.